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Vascular Dysmorphogenesis Caused
by an Activating Mutation
in the Receptor Tyrosine Kinase TIE2
Miikka Vikkula,1,7 Laurence M. Boon,1,2,7,8 tubes (Risau and Lemmon, 1988; Risau et al., 1988; No-
den, 1989). This retiform plexus undergoes remodelingKermit L. Carraway III,3 Jennifer T. Calvert,4
A. John Diamonti,3 Boyan Goumnerov,5 and forms the complex network of adult vasculature
through angiogenesis, the sprouting of new blood ves-Krystyna A. Pasyk,6 Douglas A. Marchuk,4
Matthew L. Warman,1,9 Lewis C. Cantley,3 sels from preexisting ones (Risau et al., 1988; Noden,
1989).John B. Mulliken,2 and Bjorn R. Olsen1
1 Department of Cell Biology Formation of endothelial tubes is followed by recruit-
ment of pericytes and smooth muscle cells (SMCs) fromHarvard Medical School
Harvard-Forsyth Department of Oral Biology mesenchymal progenitor cells and neural crest cells
Harvard School of Dental Medicine (Nakamura, 1988; Kirby and Waldo, 1995). ECs are be-
Boston, Massachusetts 02115 lieved to play an important role in regulating this recruit-
2 Division of Plastic Surgery ment. For example, in EC–SMC cocultures, ECs stimu-
Children’s Hospital late proliferation (Fillinger et al., 1993) and induce
Harvard Medical School migration of SMCs (Powell et al., 1996a). Furthermore,
Boston, Massachusetts 02115 in organ cultures of human saphenous veins, denudation
3 Department of Cell Biology of the endothelium results in decreased proliferation of
Harvard Medical School intimal SMCs (Allen et al., 1994). ECs can also modulate
Division of Signal Transduction the morphology of SMCs from a synthetic to a contrac-
Beth Israel–Deaconess Hospital tile phenotype (Powell et al., 1996b).
Boston, Massachusetts 02115 Several cytokines and growth factors have been impli-
4 Department of Genetics cated in these effects. Platelet-derived growth factor
Duke University Medical Center (PDGF) expressed by ECs acts as a mitogen and chem-
Durham, North Carolina 27710 oattractant for mesenchymal cells in vitro (Grotendorst
5 Department of Pathology et al., 1981; Grotendorst et al., 1982; Westermark et al.,
Children’s Hospital 1990). Another growth factor, transforming growth factor
Harvard Medical School b1 (TGFb1), also known to be produced by ECs, induces
Boston, Massachusetts 02115 differentiation of neural crest cells into SMCs (Shah et
6 Institute of Gerontology al., 1996). Signaling from the mesenchymal cells and
University of Michigan extracellular matrix to endothelium is also likely, since
Ann Arbor, Michigan 48109 a single cell population, the hemangioblasts, gives rise
to ECs in arterial, capillary, venous, and lymphatic ves-
sels, which are known to differ in their pattern of gene
Summary expression. For example, lymphatic ECs have high ex-
pression of VEGFR-3/FLT-4, whereas the expression of
Venous malformations (VMs), themost common errors this cytokine receptor in veins and arteries is almost
of vascular morphogenesis in humans, are composed undetectable (Kaipainen et al., 1995). Furthermore, ex-
of dilated, serpiginous channels. The walls of thechan- tracellular matrix can modulate the effects of ECs on
nels have a variable thickness of smooth muscle;some SMC migration and adhesiveness (Powell et al., 1996a),
mural regions lack smooth muscle altogether. A mis- and EC proliferation can be inhibited by contact with
sense mutation resulting in an arginine-to-tryptophan SMCs and pericytes (Orlidge and D’Amore, 1987). As a
substitution at position 849 in the kinase domain of result, there are structural differences in the walls of
the receptor tyrosine kinase TIE2 segregates with mature vessels in different segments of the vascular
dominantly inherited VM in two unrelated families. Us- tree, and cell signaling pathways are likely to differ in
ing proteins expressed in insect cells, we demonstrate morphologically or functionally distinctive segments of
that the mutation results in increased activity of TIE2. the vascular system.
We conclude that an activating mutation in TIE2 Genetic vascular disorders in humans provide molec-
causes inherited VMs in the two families and that the ular insights into these pathways. For example, heredi-
TIE2 signaling pathway is critical for endothelial cell– tary hemorrhagic telangiectasia (Rendu-Osler-Weber
smooth muscle cell communication in venous mor- syndrome), in which there is a gradual alteration in the
phogenesis. capillary bed between venules and arterioles, has been
shown to be caused by mutations in two TGFb binding
proteins, endoglin and activin receptor–like kinase
Introduction (McAllister et al., 1994; Johnson et al., 1996). As a result
of localized capillary dilatation, arterial blood is shunted
Vascular morphogenesis begins as vasculogenesis, in directly into postcapillary venules, which in turn become
situ differentiation of endothelial cells (ECs) from hem-
angioblasts, and subsequent formation of endothelial
of Louvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium.
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convoluted and “arterialized,” manifesting increased three unaffected individuals IV-9, II-21, and IV-16 are
nonpenetrant for the disease phenotype.smooth muscle within their walls. These findings sug-
gest that TGFb signaling pathways are crucial for the
development and maintenance of normal capillary beds. The Receptor Tyrosine Kinase TIE2 Gene
In ataxia–telangiectasia, intracellular signaling errors Is Localized within the VMCM1 Locus
due to mutations in a protein kinase/phosphatidylinosi-
For positional cloning and candidate gene identification,
tol kinase homolog cause abnormalities in cell cycle
we obtained two human melanoma cell lines (MN455
control, resulting in telangiectases (Savitsky et al., 1995). and W) containing previously defined homozygous dele-
Venous malformation (VM) is the most common devel- tions of 9p and a YAC contig covering the 8 cM region
opmental vascular anomaly. VMs are usually sporadic from the IFN gene cluster to the marker D9S161 (gener-
and solitary, but they can also be familial and typically ously provided by Dr. Frank Haluska). The EC-specific
are multifocal. They are usually located in skin and mu- receptor tyrosine kinase TIE2 gene had been mapped
cosal membranes, but any organ can be affected (Mulli- previously to 9p21 by in situ hybridization (Dumont et
ken and Young, 1988). VMs are seen either at birth or al., 1994); we wanted to test whether it was localized to
later in life. The molecular basis for VMs is unknown. the linked interval. Using DNA from the cell lines and
To gain insight into the cause of VM, we have studied YAC clones as template for polymerase chain reaction
two unrelated families with dominantly inherited muco-
(PCR), we found that DNA from cell line MN455 was
cutaneous VMs. Using random linkage mapping, we
positive for TIE2, whereas DNA from cell line W was
found that the locus for a gene causing the malforma-
negative. Since cell line MN455 has a deletion of the
tions is on the short arm of chromosome 9 (Boon et al.,
IFN gene cluster and cell line W is deleted between
1994; Gallione et al., 1995). Here we report that the
IFNA and D9S3, the TIE2 gene had to lie between these
receptor tyrosine kinase TIE2 gene is localized within markers. Of the 24 tested YAC clones, IG4D7, 7I1C4,
this locus, and that a C-to-T nucleotide transition, lead- 874c7, 822f8, 899b9, and 882f4 were positive with TIE2-
ing to an arginine-to-tryptophan substitution at position specific PCR. Since these clones were also positive
849 (R849W) in the kinase domain of the receptor, co- for D9S169 (located between IFNA and D9S3), and the
segregates with the phenotype in the two families. Fur- smallest of the clones, 874c7, was 560 kb in size, the
thermore, by using a baculovirus expression system, we TIE2 gene had to lie in the vicinity of this marker within
demonstrate that the R849W change causes increased the linked interval.
activity of the TIE2 kinase. Using immunohistochemistry
of lesions, we also show that affected vessels contain
A Single Nucleotide Change in TIE2a disproportionately large number of ECs versus SMCs.
Segregates with the PhenotypeTherefore, we conclude that the developmental venous
in Two Unrelated VM familiesanomalies in the two families are caused by local uncou-
To analyze TIE2 as a candidate gene in the two VMpling between the normal recruitment of SMCs and the
families, we used Epstein-Barr virus to transform lym-proliferation of ECs. This uncoupling is due to an activat-
phocytes taken from two patients in family SA (individu-ing mutation in TIE2 and indicates that the TIE2 signaling
als III-7 and II-13, Figure 1), one patient in family AFpathway is crucial for the normal development of veins.
(individual IV-13, Figure 1B), and control individuals. We
extracted total RNA from the cultured cells and used it
as template for reverse transcription PCR. PCR primersResults
for nine overlapping fragments were synthesized to
cover the whole 3375 bp coding sequence of the TIE2Inherited VM in Two Families Is Linked
to an Interval on Chromosome 9p21 gene. Cycle sequencing of these products identified:
two nucleotide polymorphisms that do not change theWe have described linkage of inherited VM in two fami-
lies to markers on the short arm of chromosome 9 codon for an amino acid (G1962A and G2322A); a single–
amino acid–deletion polymorphism (valine 788; bovine(VMCM1; OMIM number 600195) (Boon et al.,1994; Galli-
one et al., 1995). The linked interval was defined by and rat sequences have the valine residue and the mu-
rine does not); and a T2084C change resulting in anrecombinant markers D9S157 and D9S161. We evalu-
ated 35 additional members of the family SA (Figure isoleucine-to-threonine substitution that was confirmed
to be homozygous in our samples and in a partial human1A) and narrowed the interval to 8 centimorgans (cM)
between the IFN gene cluster and marker D9S161 (data TIE2 clone (kindly provided by Dr. Kari Alitalo). In the
murine, bovine, and rat sequences, a threonine residuenot shown). Three members of family SA and one mem-
ber of family AF were recombinant for the entire interval. is found at this position, suggesting that threonine 2084
is an error in the previously published human sequence.Individual II-15 in family SA had a single cervical lesion
but had not inherited thehaplotype linked to the disease, We also identified a C-to-T transition at position 2545
that changes an arginine to a tryptophan residue (Figurewhereas unaffected individuals IV-9, a 14-year-old boy,
and II-21, an 81-year-old man, had inherited the haplo- 2A). To confirm that the C2545T transition was present
in genomic DNA and that this nucleotide substitutiontype. The cervical lesion in individual II-15 appeared in
early adulthood, whereas lesions in her relatives were cosegregatedwith thephenotype in family SA, we tested
all 61 family members with allele-specific PCR (Figuremultiple and became apparent clinically at an earlier
age. It is therefore probable that she represents a spo- 2B). All affected individuals carried this change, except
II-15, who was recombinant for the whole region. Inradic case. Individual IV-16, an unaffected 32-year-old
woman in family AF, also had inherited the haplotype addition, the unaffected individuals IV-9 and II-21carried
this nucleotide substitution. We also tested 138 controllinked to the disease (Figure 1B). We assume that the
A TIE2 Mutation Causes Vascular Dysmorphogenesis
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Figure 1. Family Pedigrees
(A) Family SA pedigree. Members reported previously are clustered
in the upper left corner (delineated by a dotted line). (B) Family
AF pedigree. The dots indicate family members who have been
sampled.
Standard symbols and nomenclature are used.
individuals from Canada, Finland, and the United States, the human, bovine,murine, and rat sequences (GenBank
accession numbers L06139, X71424, X71426, andbut none of them had the C-to-T transition.
To test whether the same nucleotide change, C2545T, 386048). In the homologous TIE1 receptor, the arginine
is replaced by a lysine in the human, bovine, and murineexisted in family AF, genomic DNA from all family mem-
bers was amplified and evaluated with a MaeIII restric- sequences (GenBank accession numbers X60957,
X71423, and X71425). This suggests that a basic residuetion fragment–length analysis, since the mutation de-
stroys a MaeIII site. All affected individuals as well as in this position is important for the kinase structure or
function.the unaffected individual IV-16 were heterozygous for
the substitution. To rule out that this nucleotide change To study the biochemical effect of this change on
kinase function, we cloned the full-length wild-type andwas a founder mutation and that the two families may
be related, we genotyped affected individuals from both mutant TIE2 cDNA into a baculovirus expression vector.
Recombinant viruses were obtained and several clonesfamilies for the sizes of associated STRP alleles. The
linked haplotypes differed from each other both for were purified. Using rabbit anti-TIE2 antibody (Santa
Cruz), TIE2 protein was immunoprecipitated from in-flanking markers as well as for an intragenic nucleotide
polymorphism (Figure 3). sect cell extracts. Western blotting showed a specific
140 kDa band, the expected size for TIE2 (Figure 4A);
immunoblotting with anti-phosphotyrosine antibodiesThe R849W Mutation in TIE2 Causes
Kinase Activation showed that both wild-type and mutant receptors in
the extracts were autophosphorylated, but the mutatedThe mutated arginine 849, located six amino acid resi-
dues upstream of the invariant lysine in the first intracel- receptor protein was phosphorylated to a higher extent
than the wild-type protein (data not shown). In addition,lular kinase domain of TIE2 (see below), is conserved in
Cell
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when the immunoprecipitates were incubated with veins and arteries with normal structure were seen adja-
cent to abnormal channels within the tissue specimens[g-32P]ATP before gel electrophoresis, autoradiography
suggested that the mutant receptor had a 6- to 10- (Figure 5C).
Immunostaining with antibodies against CD31 (datafold higher autophosphorylation activity in vitro than the
wild-type receptor (Figure 4A). not shown) and von Willebrand factor (vWF) showed
specific staining of the luminal cells lining blood vesselThe wild-type and mutant receptorswere also incubated
with a synthetic tyrosine-oriented peptide library (Song- walls (Figure 5A). Positive vWF staining was also seen in
intraluminal platelets. With high magnification, flattenedyang et al., 1995) to assay for differences in the ability to
phosphorylate peptide substrates. The phosphorylated ECs were seen to line the abnormal channels. Endothe-
lial nuclei were located far apart from one another, butpeptides were separated from nonphosphorylated pep-
tides and sequenced. We detected no differences in there was no endothelial discontinuity.
Antibodies against SMC a-actin demonstrated spe-specificity between the wild-type and mutant receptors.
However, the mutant protein was much more active at cific but patchy and irregular staining of the abnormal
channels as compared with the uniform layer of stainedphosphorylating peptides in the library (Figure 4B).
cells around normal veins (Figures 5B and 5C). In the
abnormal channels the staining intensity varied with theVMs Contain a Disproportionately High
size of the vessels. Small channels typically showedRatio of ECs to SMCs
prominent staining, as compared to larger channels,VMs excised from members of family SA showed dilated
some of which were devoid of a-actin staining. Scat-vascular channels of variable diameter (Figures 5A and
tered SMCs were discernible at high magnification. Dis-5B). Specimen II-7 exhibited only few ectatic veins,
organized smooth muscle was seen in the adjacent ves-whereas specimen II-8, taken from a large anomaly af-
sel wall whenever there was evidence of a muralfecting one third of the tongue (for clinical picture, see
thrombus, a pathognomonic finding in VMs.Boon et al., 1994), and specimen II-5 (Figure 5) were
composed of numerous serpiginous channels. Of note,
Discussion
VM Is Caused by a Mutation in the TIE2
Receptor Tyrosine Kinase
Based on the localization of the TIE2 gene in the minimal
candidate interval of 8 cM, the identification of the same
nucleotide transition in affected individuals of two unre-
lated families, and the increased kinase activity of the
mutant receptor in vitro, we conclude that VMs are
caused by a mutation in the TIE2 receptor. This is sup-
ported by the EC-specific expression pattern of TIE2
(Dumont et al., 1995).
We have shown that a nucleotide transition, C2545T,
results in an R849W substitution. This is not a common
polymorphism because the C-to-T transition was not
detected in 138 control individuals. The same mutation
was also identified in two disparate VM families. Family
SA is of Italian origin and family AF of German origin,
and thus it is unlikely that the mutated allele could be
derived from a common ancestor. Indeed, haplotype
analyses of flanking markers and an intragenic polymor-
phism demonstrated that the mutations occurred in two
Figure 2. Detectionof the Missense Mutation
in TIE2 in Family SA
(A) Sequencing gel showing the C-to-T
change (arrow) in two affected individuals of
family SA (lanes 2 and 3). C, control. (B) Allele-
specific PCR of 19 individuals of family SA
(see Figure 1A) showing amplification of the
mutant allele (193 bp) with an internal control
(800 bp). VI, size marker; plus, carrier; minus,
normal; question mark, sample did not work.
A TIE2 Mutation Causes Vascular Dysmorphogenesis
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Figure 3. Haplotypes of Linked Alleles for One TIE2 Intragenic Poly-
morphism (G2322A) and Five Flanking Markers in the Two Unrelated
VM Families
The C2545T mutation is flanked by different alleles of the intragenic
G2322A polymorphism andeither D9S169 orGATA165A11 in the two
families, since the orientation of the TIE2 gene on the chromosome is
unknown. TIE2 and D9S169 are maximally 560 kb apart, the size of
the smallest YAC clone, y874c7, containing both markers.
different TIE2 alleles, suggesting that the R849W change Figure 4. Comparison of the Kinase Activities of Normal and Mutant
could be localized in a mutational “hot spot.” The muta- TIE2 Receptors
tions occurred in a CpG dinucleotide, often associated (A) Lysates from Sf9 insect cells infected with wild-type baculovirus
(wt) or virus expressing normal TIE2 (R2) or mutant TIE2 (W2) werewith transitional mutations. An example of a similar “hot
immunoprecipitated with anti-TIE2 antibody and incubated with ra-spot” is achondroplasia, in which up to 97% of the
diolabeled ATP. Precipitates were subjected to autoradiographymostly sporadic, de novo mutations result in substitu-
(right) and blotted with anti-TIE2 (left).
tion of a single amino acid residue (G380R) in the trans- (B) Anti-TIE2 immunoprecipitates described in (A) were used to
membrane domain of fibroblast growth factor receptor phosphorylate an oriented random peptide library. Shown is the
3 (FGFR3) (Bellus et al., 1995). observed peptide phosphorylation for each of the precipitates, nor-
malized to the activity associated with the wild-type TIE2 receptor.Of note, a single–amino acid–length polymorphism
Since the expression levels of R2 are 2- to 3-fold higher than thosewas also identified in the kinase domain of the TIE2
of W2, the autophosphorylation and substrate phosphorylation ac-receptor. The polymorphic valine residue (788) is not
tivities of mutant TIE2 are 6- to 10-fold those of wild-type receptor.
present in the murine TIE2 sequence but is present in Error bars, standard error of three independent experiments.
the bovine and rat TIE2. The length variations between
the murine, human, and bovine sequences (1122, 1124,
overexpressed, even without ligand. It has been sug-and 1125 amino acid residues, respectively) suggest
gested that receptors that need ligand binding for dimer-that small differences in the number of amino acids can
ization and subsequent autophosphorylation have aoccur without interruption of the function of the protein.
weaker intrinsic inhibitory mechanism of autophosphor-We confirmed that it is a polymorphism by identifying
ylation (Mohammadi et al., 1996). This may be true forhomozygous and heterozygous individuals for the ab-
TIE2, which is believed to form dimers after ligandsence of valine 788.
binding.
How does the R849W change increase kinase activ-
ity? The substituted arginine 849 is located six residuesThe R849W Mutation Causes Increased
Phosphorylation Activity of TIE2 upstream of the invariant lysine in the kinase domain
and is conserved among human, bovine, murine, andOverexpression studies of full-length wild-type and mu-
tant receptors in insect cells showed an increase in rat TIE2 sequences; in the homologous receptor, TIE1,
another basic amino acid residue, lysine, is found atautophosphorylation activity for the mutant form. Not
only was the mutant protein more phosphorylated than the same position in the human, bovine, and murine
sequences. This suggests that a basic residue is impor-the wild-type protein when assayed directly by immu-
noblotting of insect cell extracts, it also showed a 6- to tant at this position. In the crystal structure of the FGFR1
kinase domain, an arginine residue, 38 amino acid resi-10-fold higher autophosphorylation activity in vitro when
incubated with [g-32P]ATP. Like many other growth fac- dues upstream of the invariant lysine, is found hydrogen-
bonded to the carbonyl group of a downstream prolinetor receptors, TIE2 is easily autophosphorylated when
Cell
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Figure 6. Kinase Domain Structure and Partial Amino Acid Se-
quence
(Top) Ribbon structure of the insulin receptor kinase domain, illus-
trating the location of the activating mutation in the TIE2 receptor
kinase. The amino-terminal lobe is depicted in blue and the carboxy-
terminal lobe is depicted in green. The side chains of amino acid
residues involved in catalysis (Glu 1047, Asp 1132, Asn 1137, and
Asp 1150) are depicted in red. The conserved lysine residue neces-
sary for activity (Lys 1030) is shown in purple. A glutamicacid residue
(Glu 1024) corresponding to the residue mutated in TIE2 is depicted
by orange space-filling atoms, emphasizing that this residue is at
a position distal to the catalytic cleft. A lysine residue (Lys 1126)
corresponding to the K650E mutation in the activation loop of FGFR3
is illustrated with yellow space-filling atoms.
(Bottom) Amino acid sequences in the region of the R849W mutation
are shown for five human tyrosine kinase receptors, including the
insulin receptor. The invariant lysine (K) residue and the arginine (R)
849 in TIE2 are indicated by boxes.
Figure 5. Immunohistochemistry of VM Lesion with Antibodies
against vWF (A) and SMC a-Actin (B and C) of this domain so that intrinsic inhibitory mechanisms
(A) Staining with vWF antibodies shows a continuous covering of are diminished, resulting in increased autophosphoryla-
ECs in the large veins. (B) In contrast, staining with antibodies tion. Alternatively, replacement with a more hydrophobic
against a-actin shows that the malformed veins contain regions of residue (tryptophan) could induce receptor dimerization
disorganized SMCs (arrowhead), regions with no detectable staining
in theabsence of ligand and result in increased autopho-(arrow), and regions with a thin, uneven layer of smooth muscle
sphorylation. It is noteworthy that when the TIE2 se-(asterisks). (C) Normal veins (v) and arteries (a) are found adjacent
quence is superimposed onthe crystal structure of otherto the malformed veins within the specimen. Scale bars, 200 mM.
kinase domains, arginine 849 is located on an outward
curving loop (Figure 6), a loop that could be involved in
dimerization.residue, suggesting an important role in the stabilization
of the amino-terminal lobe of the kinase domain (Mo- A graded activation of receptor function is seen with
certain amino acid substitutions in FGFR3 that causehammadi et al., 1996). If arginine 849 in TIE2 is involved
similarly in stabilizing the kinase domain, it could be that osteochondrodysplasias of differing severity (Naski et
al., 1996; Webster et al., 1996). One of these mutations,its substitution by tryptophan alters the conformation
A TIE2 Mutation Causes Vascular Dysmorphogenesis
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G380R, the cause of achondroplasia, is located in the
transmembrane domain and has a weak activating effect
on the receptor, resulting in 15%–20% ligand-indepen-
dent mitogenic activity. Another mutation, K650E, lo-
cated in the activation loop of the FGFR3 kinase domain
(Figure 6), results in a 100-fold increase in autophos-
phorylation (Webster et al., 1996). Of note, when a num-
ber of other residues in the region of lysine 650 (the
b10–b11 region) were mutated to glutamine, no activa-
tion of the kinase was observed (Webster et al., 1996).
Thus, mutations involving residues only at specific loca-
tions in FGFR3 alter kinase activity. The R849W mutation
in TIE2 may represent a similar case.
Based on the observations of FGFR3 mutations, it has
Figure 7. Hypothesis for Coupling of TIE2-Based Signaling in ECsbeen postulated that they differentially affect dimeriza-
with Recruitment of SMCs in the Vascular Walltion of the receptor and that increasing the amount of
We hypothesize that expression of the TIE2 ligand in mesenchymalmutated protein would result in increased dimerization
cells is controlled by negative feedback from ECs and that this
and activation (Naski et al., 1996). If a similar ligand- TIE2–ligand loop is coupled to PDGF/TGFb–mediated chemotaxis,
independent dimerization explains how the TIE2 muta- proliferation, and differentiation of SMCs.
tion causes the vascular changes seen in mucocutane-
ous VM, it might also explain why these malformations
may therefore lead to abnormal sprouting, branching,are localized and variable in number, shape, and size.
and remodeling. We believe that the dominantly inher-If homodimers of mutant subunits are more active than
ited R849W substitution in the two VM families repre-homo- and heterodimers containing wild-type protein,
sents such a gain of function mutation. The lesions con-focal stochastic variations in the expression of the wild-
tain large venous channels with a disproportionately lowtype and mutant alleles could change receptor activity
number of SMCs.Whether the formation of the abnormaland thus locally modulate TIE2 signaling in ECs. Loss
vessels involves abnormal local proliferation of ECs isof the wild-type allele (dueto a somatic mutation), similar
not known. VM endothelium in a specimen from anto that recently reported for defects in Gorlin’s syndrome
8-year-old girl stained negatively for two proliferating(Levanat et al., 1996), may also result in clonal expansion
cell markers (Ki-67 and E-selectin) (Kraling et al., 1996),of ECs expressing only the mutant receptor. Such varia-
possibly because the VMs examined were established,tion in expression could also explain why three family
not growing, lesions.members were carriers of the mutation yet clinically
It is likely that theactivity of theTIE2 signaling pathwayunaffected, reducing the observed penetrance to 94%.
is at least partially regulated by surrounding mesen-
chyme since ligands that activate TIE2 are expressed
by mesenchymal cells (Davis et al., 1996 [this issue ofThe Disproportionate Number of ECs and SMCs
in VMs Is Caused by Activation of TIE2 Cell]). Thus, TIE2 signaling in ECs and expression of the
ligands inmesenchymal cells are linked. We hypothesizeImmunohistochemical analysis showed that the dis-
tended vascular channels contain a continuous EC layer that ligand expression is controlled by a feedback loop,
with an EC signal negatively affecting the expression ofsurrounded by a highly variable thickness of smooth
muscle. Some areas of the channel walls contain a rela- ligands by SMCs (Figure 7). Furthermore, we suggest
that the TIE2 loop is coupled to EC-controlled SMCtively normal number of SMCs, whereas other regions
are totally devoid of muscle (Figure 5). The structure of chemotaxis, proliferation, and differentiation during nor-
mal morphogenesis of veins and that it is uncoupledthe SMC layer is also disorganized. The diameter of
the abnormal vessels can be ten times that of normal in VMs, since the malformations appear to contain a
disproportionate number of ECs relative to investingchannels, suggesting that the dysmorphogenesis in-
volves abnormal venous growth or remodeling caused smooth muscle.
Numerous in vitro and in vivo studies show that PDGFby a local uncoupling between proliferation and differen-
tiation of ECs and SMCs. and TGFb play major roles in controlling SMC che-
motaxis, proliferation, and differentiation. ExogenousWhat is already known about the TIE2 signaling path-
way supports the hypothesis that it is essential for early PDGF can act as a mitogen and chemoattractant for
SMCs and pericytes (Grotendorst et al., 1981; Groten-vascular development. TIE2 knockout mice and mice
with a dominant-negative mutation in TIE2 have 30% dorst et al., 1982; Westermark et al., 1990; D’Amore
and Smith, 1993). SMCs, reciprocally, can regulate ECand 75% fewer ECs in embryos at days 8.5 and 9.0,
respectively, when compared to wild-type embryos (Du- expression of PDGF-B, suggesting that there is a feed-
back loop between the cells in vivo (Bonin and Damon,mont et al., 1994). The knockout embryos as well as the
transgenic embryos dieat about embryonic day 9.5–10.5 1994). Furthermore, the expression patterns of PDGF-B
and its receptor PDGFbR in angiogenic ECs and sur-with malformation of the vascular network (Dumont et
al., 1994; Sato et al., 1995), and it has been suggested rounding mesenchymal cells as well as data from mice
with inactivated PDGF-B and PDGFbR alleles suggestthat TIE2 signaling is important for sprouting and
branching or remodeling of the primary capillary plexus that PDGF plays an important role in vascular morpho-
genesis (Holmgren et al., 1991; Shinbrot et al., 1994;(Sato et al., 1995). A gain of function mutation in TIE2
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Analysis of the TIE2 GeneSoriano, 1994; Leveen et al., 1994). TGFb1 has been
Total RNA was extracted from Epstein-Barr virus–transformedshown to be an inhibitor of proliferation of SMCs, though
lymphoblasts or peripheral blood leukocytes according to the acid-not of pericytes, and a chemoattractant for SMCs (Mer-
guanidinium-thiocyanate extraction protocol (Chomczynski and
win et al., 1991; D’Amore and Smith, 1993). Also, TGFb Sacchi, 1987). Five micrograms of total RNA were used as template
is activated in EC–-SMC cocultures (Antonelli-Orlidge for cDNA synthesis with oligo(dT) primer using the Superscript Pre-
amplification System (GIBCO–BRL).et al., 1989) and TGFb1 is believed to be a regulator of
Nested PCR reactions were performed in a total volume of 50SMC differentiation (Desmouliere et al., 1993). Based on
ml under the conditions described above. First-round PCRs werethese data, we propose that the TIE2 signaling pathway
performed for 40 cycles and second-round PCRs for 35 cycles. Theis coupled to PDGF/TGFb–based recruitment of SMCs
cycles consisted of 948C for 1 min, 568C or 608C for 1 min (608C for
during vascular morphogenesis (Figure 7). Whether this 1 min for all second rounds), and 728C for 2 min (1 min for all second
coupling occurs at the level of endothelial or mesenchy- rounds), followed by a final extension step at 728C for 10 min.
Primers for the first-round PCR reactions were designed so thatmal cells is not clear. If the coupling mechanism is local-
the 3375 bp coding sequence was amplified in five overlappingized in ECs, linking PDGF expression to signaling
fragments. Two nested primer pairs were used for all but the mostthrough TIE2, it would be predicted to be a negative
39-end amplification product, yielding nine different second-roundcoupling, since the activating TIE2 mutation in VM
fragments. The primers used for PCR and sequencing were as fol-
causes hypoplasia of SMCs and not hyperplasia. This lows (nucleotide positions refer to published cDNA sequence Gen-
possibility is perhaps less likely, since PDGF expression Bank number L06139, nucleotide number 1 being the adenine in the
translation start codon ATG at position 149 in sequence L06139):is usually upregulated in proliferating ECs (Betsholtz,
TIE2-1 (antisense) 59-TTCTCAGCAGTTGTCAAGGG (nt: 3443–3424);1993).
TIE2-2 (sense) 59-AACCAGCTGTGCAGTTCAAC (nt: 2372–2391);The activating mutation in TIE2 is predicted to result in
TIE2-5 (antisense) 5-9TGCCATCCTGGAGAGCAGAG (nt: 1007–988);a decreased expression of TIE2 ligands in mesenchymal
TIE2-6 (sense) 59-TGTGAAGCCCAGAAGTGGGG (nt: 631–650);
cells. The more likely possibility is therefore a mecha- TIE2-7 (sense) 59-GGACCTCATGCACATTTGTG (nt: 248 to 228);
nism that positively couples expression of TIE2 ligands TIE2-8 (antisense) 59-ACCCATCCTTCTTGATGCGC (nt: 2542–2523);
TIE2-9 (sense) 59-TCTCAAGCACCAGCGGACCT (nt: 2203–2222);in mesenchymal cells with their PDGF/TGFb–mediated
TIE2-10 (antisense) 59-ACTGCAGACCCTTCCAGCCT (nt: 892–873);migration, proliferation, and differentiation. If this is the
TIE2-11 (antisense) 59-CAATGTGCAATACATGTAGGG (nt: 3880–case, down-regulation of TIE2 ligand expression (as we
3860); TIE2-12 (sense) 59-ATTGTCCCGAGGTCAAGAGG (nt: 2952–predict for VM) should result in decreased SMC recruit-
2971); TIE2-13 (sense) 59-GCAAGAATGAAGACCAGCAC (nt: 2033–
ment (as we observe in VM), whereas up-regulation of 2052); TIE2-14 (antisense) 59-ACAAGTCATCCCGCAGTAGG (nt:
TIE2 ligand expression in mesenchymal cells should re- 3132–3113); TIE2-15 (antisense) 59-TCCAGCAGAGCCAAGGATGG
(nt: 2268–2249); TIE2-16 (antisense) 59-GAGGGTCACCAGTTCATsult in increased SMC recruitment. Mice carrying condi-
GAG (nt: 2196–2177); TIE2-17 (sense) 59-TATTCACCATCCACCGGtional knockout alleles or inducible transgenes of TIE2
ATC (nt: 1223–1242); TIE2-18 (sense) 59-ACTCAGGAGTTTGGGTCand TIE2 ligands should be useful in further studies of
TGC (nt: 1253–1272); TIE2-19 (sense) 59-TCCTGCCTAAAAGTCAGthese possibilities.
ACC (nt: 1652–1671); TIE2-20 (antisense) 59-AGCACCGAAGTCAAGT
TGCC (nt: 1802–1783); TIE2-21 (antisense) 59-TGATTGGTCCATCCC
CAAAG (nt: 1429–1410); TIE2-22 (antisense) 59-GCTCAGAGCTGATG
Experimental Procedures TTGATG (nt:1405–1386); TIE2-23 (sense) 59-TGCGTCAACAAGCTTC
CTTC (nt: 353–372); TIE2-24 (sense) 59-TATGACTGTGGACAAGG
Family Members GAG (nt: 390–409); TIE2-25 (sense) 59-AGAAAGGTGCAGTGGAC
Informed consent was obtained for each family member participat- AAG (nt: 795–814); TIE2-26 (antisense) 59-GCATGAGGCAGGTGTAC
ing in this study. For family SA (Figure 1A), we collected blood TTC (nt: 542–523); TIE2-27 (sense) 59-TGGAAAGTCACAAACCGCTG
samples from 35 additional family members not previously reported.
(nt: 288 to 269); TIE2-28 (antisense) 59-GGGCACTGAATGGATGA
The Puregene kit was used for DNA extraction following the protocol
AGG (nt: 498–479); TIE2-29 (sense) 59-TTCAGTATCAGCTCAAGGGC
supplied by the manufacturer (GENTRA Systems). Genotyping of
(nt: 2084–2103); TIE2-30 (antisense) 59-GTGTGCCTCCTAAGCTA
individuals for markers in the 9p region was performed as described
ACA (nt: 3112–3093); and TIE2-31 (antisense) 59-TCATTCTTTTGATG
earlier (Boon et al., 1994).
GCAGCATC (nt: 2572–2551).
The five primer pairs used for the first-round PCRs were TIE2-11/
TIE2-12, TIE2-13/TIE2-14, TIE2-15/TIE2-17, TIE2-21/TIE2-23, andLocalization of the TIE2 Gene
TIE2-26/TIE2-27. The nested primer pairs used for the second-roundTo test whether the TIE2 gene is localized in the linked region, we
PCR for each of these first-round PCRs were, respectively, TIE2-3/obtained DNA from two human melanoma cell lines known to contain
TIE2-4, TIE2-1/TIE2-12, TIE2-2/TIE2-30, TIE2-8/TIE2-29, TIE2-16/homozygous deletions of the 9p region and from 20 YAC clones
TIE2-19, TIE2-18/TIE2-20, TIE2-10/TIE2-24, TIE2-22/TIE2-25, andlocated to the same region (kindly provided by Dr. Frank Haluska,
TIE2-7/TIE2-28.Massachusetts Institute of Technology). Cell line W was positive for
To sequence the mutation site from genomic DNA, primers TIE2-IFNA and D9S161 but negative for markers D9S171 and D9S169.
2570 (sense) 59-TCAGGGACTCTGGCCCTAAACAG (nt: 2392–2414)Cell line MN455 was negative for markers telomeric from D9S171,
and TIE2-577-ER (antisense) 59-ATATTCTTTCATTCTTTTGATGincluding IFNA (F. G. Haluska, unpublished data).
GCAGCATC (nt: 2580–2551) were used. Allele-specific PCR wasPCR was performed with primers TIE2-3 (sense) 59-GCAGGAATT
used to screen family members and controls. Two additional primersGACTGTTCTGC (nt: 3488–3507) and TIE2-4 (antisense) 59-ATGTCTC
with similar estimated annealing temperatures were synthesized:CCAAATGTCACCC (nt: 3981–3962), resulting in a 0.9 kb product
TIE2-R (antisense) 59-TTGATGGCAGCATCCATCCG (nt: 2564–2545),with genomic DNA as template. PCR reactions were performed in
TIE2-W (antisense) 5-9TTTGATGGCAGCATCCATCCA (nt: 2565–a total volume of 25 ml containing 1 3 PCR buffer (Perkin-Elmer),
2545). The analyses were performed using two separate PCRs for200 mM dNTPs, 0.5 mM each primer, and 1 U of Taq polymerase.
each template: TIE2-2/TIE2-R or TIE2-2/TIE2-W, both containing anThe 35 cycles consisted of 948C for 30 s, 548C for 30 s, and 728C
internal control, TIE2-6/TIE2-10 (Figure 2B). The reaction conditionsfor 40 s, followed by a final extension step at 728C for 10 min. To
were the same as mentioned above, except that the nucleotidereveal the minimal region where the TIE2 gene can be localized,
concentration was 40 mM. Each cycle of the PCR consisted of 958Cfour additional YAC clones were obtained: 874c7, 822f8, 899b9,
for 1 min, 688C for 1 min, and 728C for 1 min (30 cycles), with a finaland 882f4 (Ge´ne´thon; clones kindly provided by Dr. J. Vance, Duke
University). extension at 728C for 10 min. Cosegregation of the mutation in family
A TIE2 Mutation Causes Vascular Dysmorphogenesis
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AF was studied using MaeIII restriction enzyme digestions of TIE2- antimouse antibody (Promega), were kindly provided by Dr. K. Taka-
hashi (Takahashi et al., 1994).2570/TIE2-577-ER amplification products. This 189 bp PCR product
contains one MaeIII site (at nt 149) that is abolished by the mutation. Prior to staining for antibodies, the tissues were incubated with
250 mg/ml protease (Sigma Chemical) for 6 mins. Blocking was
performed by incubating the slides in 5% skim milk with PBS for 1Construction of Full-Length Clones of the TIE2 Gene
hr. Primary antibodies (diluted 1:100 in PBS) were applied at 48Cand Their Expression Using a Baculovirus
for 12 hr. After washing with PBS, the secondary antibody (dilutedExpression System
1:100 in PBS) was applied for 1 hr at room temperature. Fast-redTo clone the 3375 bp coding sequence of the TIE2 gene, cDNA
chromogen (Dako) was used for visualization of the immunoreac-synthesized as described above was used as template for nested
tions. The reactions were terminated by adding water, and the slidesPCR. First-round PCR using primers TIE2-4/TIE2-27 and second-
were mounted using Permount (Fisher Scientific).round PCR with primers TIE2-1/TIE2-7 were performedunder condi-
tions as described above, except that Taq extender was used ac-
cording to the manufacturer’s directions (Stratagene). Each cycle Acknowledgments
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